tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability
PremiumRatingsPromising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability
1M ago
Enliven reports Q3 EPS (32c) vs. (48c) last year
Premium
The Fly
Enliven reports Q3 EPS (32c) vs. (48c) last year
1M ago
Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
Premium
Ratings
Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
2M ago
Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
PremiumThe FlyEnliven, Novartis drugs poised to lead in CML markets, says Clear Street
2M ago
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
Premium
Ratings
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
4M ago
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
Premium
Ratings
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
4M ago
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
PremiumCompany AnnouncementsEnliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
5M ago
Enliven Therapeutics’ Promising CML Treatment: A Study Update
Premium
Company Announcements
Enliven Therapeutics’ Promising CML Treatment: A Study Update
5M ago
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
Premium
Company Announcements
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100